Data from the RATIONALE 305 trial support the approval of tislelizumab/chemotherapy in unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma.
Approval Alert | Tislelizumab/Chemotherapy in Gastric/GEJ Adenocarcinoma
Advertisement
Advertisement
Trending on CancerNetwork
1
Modifiable Risk Factors Suggest Potential for Improving Cancer Prevention
2
Exploring The Impact of ADTs on Cardiac Risk in Prostate Cancer Treatment
3
Barriers to CAR T-Cell Referral and Center Access in Multiple Myeloma
4
2026 Tandem Meetings: What’s the Latest Research in Multiple Myeloma?
5